Akeso, Summit cancer drug confirms lung cancer survival benefit
Source ↗
👁 0
💬 0
A new data cut of a trial pitting ivonescimab, a bispecific antibody, against Merck’s Keytruda showed the new drug helped people live longer.
Comments (0)